Cholesterol rises at menopause, not with age — and the sharpest change lands within a year of the final period
In short
During the menopause transition, falling oestrogen drives significant increases in LDL cholesterol and triglycerides, while HDL cholesterol changes in composition and function so that it protects the cardiovascular system less well. These lipid changes occur independently of chronological ageing, and the most pronounced increases happen within one year of the final menstrual period. The review names Mediterranean and DASH dietary patterns plus regular aerobic or resistance training as evidence-based mitigations, with statins remaining first-line when lifestyle change is insufficient. Menopausal hormone therapy improves the lipid profile itself, but current guidelines do not recommend it for dyslipidemia management or cardiovascular prevention.
When cholesterol numbers worsen around menopause, most people file it under ageing. The central point of this review is that the filing is wrong. Lipid changes across the menopause transition occur independently of chronological ageing, and the increases are most pronounced within one year of the final menstrual period.
Concretely, what moves: as oestrogen declines, LDL cholesterol and triglycerides increase significantly, and HDL cholesterol changes in composition and function such that its cardioprotective properties are reduced. That last item matters most, because it is invisible if you only read the HDL number on a panel.
Why the timing is the finding
Lipid change concentrated around the menopause itself means the window to act is narrow. Read a slowly worsening panel in your late forties as one more year of ageing and you will miss a shift that actually happens over a small number of years. Read it as a datable event and the decisive question becomes whether the habits were already in place before it.
Dyslipidemia sits on the modifiable side of cardiovascular risk at this life stage. That is why the review calls this period a critical window for early prevention and intervention rather than simply a risk factor to note.
Where training fits
The evidence-based lifestyle interventions the review lists come in two parts. On diet, the Mediterranean and DASH dietary patterns. On exercise, regular aerobic or resistance training — resistance training is named alongside aerobic, not as an afterthought. Smoking cessation and limiting alcohol intake are added as further risk reduction.
What resistance training did to blood pressure and cardiac structure in postmenopausal women, across 60 studies in humans, is covered separately in resistance training and the postmenopausal heart — a different axis from lipids, and worth reading alongside this. How protein fits inside a Mediterranean pattern is in whey with a Mediterranean diet.
Drugs and hormone therapy
The review is unambiguous here. When lifestyle interventions are insufficient, statins remain first-line therapy. Menopausal hormone therapy does affect the lipid profile favourably, but current guidelines do not recommend it for dyslipidemia management or cardiovascular prevention, because the benefits are inconsistent and there are potential risks.
This is a review, not a randomised trial. It synthesises mechanisms, lipid trajectories and the impact of lifestyle and therapeutic interventions across the menopause transition; it does not report a pooled effect size of the form ‘this training programme lowers LDL by X mg/dL’. So what transfers is the timing and direction, not a numeric target. Statins and hormone therapy are entirely a conversation with a doctor, and your own numbers only exist on a blood panel.
What to record
Two records are worth keeping through this period. The first is lipid panel results dated against the menopause itself. Being able to compare before and after the final menstrual period is what separates ageing from menopause as the cause. The second is evidence that training actually continued through that same stretch.
A strength score's role here is honestly an indirect one. The score does not reflect lipids. But what this review names as a mitigation is regular training, and whether it was regular is established by a log rather than by memory. If Big 3 numbers held or rose across the two or three years spanning menopause, at minimum the training did not lapse.
Frequently asked questions
Does cholesterol rise at menopause because of age?
No. This review concludes that lipid changes across the menopause transition occur independently of chronological ageing. As oestrogen declines, LDL cholesterol and triglycerides rise, with the most pronounced increases occurring within one year of the final menstrual period.
What happens to HDL after menopause?
More than the number changes. During the menopause transition HDL cholesterol alters in composition and function, reducing its cardioprotective properties — a change that a plain HDL value on a panel does not reveal.
Can exercise slow the lipid changes of menopause?
The review names regular aerobic or resistance training, alongside Mediterranean and DASH dietary patterns, as evidence-based ways to mitigate the adverse lipid changes. As a review, it does not give a pooled effect size for any specific exercise prescription.
Is hormone therapy a way to manage cholesterol at menopause?
Current guidelines do not recommend it for that. Menopausal hormone therapy affects the lipid profile favourably, but because benefits are inconsistent and risks are possible, guidelines do not endorse its use for dyslipidemia management or cardiovascular prevention.
What if lifestyle change is not enough?
According to this review, statins remain first-line therapy when lifestyle interventions are insufficient. That decision belongs with a doctor, based on blood panel results.
Source: PubMed